Skip to main content
Fig. 2 | Clinical Epigenetics

Fig. 2

From: NEFM DNA methylation correlates with immune infiltration and survival in breast cancer

Fig. 2

Kaplan–Meier survival curves of high versus low expression of NEFM in TCGA, Human Protein Atlas and Kaplan–Meier plotter databases. (OS: overall survival; NA: not applicable; RFS: recurrence-free survival). a OS curves of BRCA in TCGA. Low NEFM mRNA expression correlated with poor OS in TCGA_BRCA cohort (median OS: 149 vs. NA months, p = 0.0017). b OS curves of BRCA in Human Protein Atlas database. NEFM protein expression correlated with favorable OS (p = 0.0014). c RFS curves of BRCA in Kaplan–Meier plotter databases (median RFS: 37.8 vs. 69.2 months, p = 1.5e-10). d OS curves of BRCA in Kaplan–Meier plotter databases (median OS: 88.67 vs. 143 months p = 0.025). er. OS curves of pan_cancer in Kaplan–Meier plotter databases. e Cervical squamous cell carcinoma; f kidney renal clear cell carcinoma; g lung adenocarcinoma; h lung squamous cell carcinoma; i pancreatic ductal adenocarcinoma; j pheochromocytoma and paraganglioma; k rectum adenocarcinoma; l stomach adenocarcinoma; m thyroid carcinoma; n uterine corpus endometrial carcinoma; o bladder carcinoma; p head–neck squamous cell carcinoma; q ovarian cancer; r Sarcoma. High NEFM expression correlated with favorable OS of pancreatic ductal adenocarcinoma, pheochromocytoma and paraganglioma, whereas with poor OS of kidney renal clear cell carcinoma, lung adenocarcinoma, stomach adenocarcinoma, bladder carcinoma, head–neck squamous cell carcinoma, ovarian cancer and sarcoma in Kaplan–Meier plotter databases

Back to article page